Certara Inc

CERT · NASDAQ

Software Publishers

Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs approved by the US FDA in the past six years were supported by Certara software or services. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries.

Market Data

Price $6.93 -0.11 (-1.56%)

Market Cap$1.12B

P/E Ratio—

EPS$—

52W High$15.38

52W Low$6.04

Beta1.52

Data from Finnhub · Updated Mar 10, 2026